Literature DB >> 17307970

Overview of PDEs and their regulation.

Kenji Omori1, Jun Kotera.   

Abstract

Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiological events in the cardiovascular system. These events are regulated by second messengers, cAMP and cGMP, in response to extracellular stimulants. The strength of signal transduction is controlled by intracellular cyclic nucleotide concentrations, which are determined by a balance in production and degradation of cAMP and cGMP. Degradation of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions. Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homology, enzymatic properties, and sensitivity to inhibitors. PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymatic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with association proteins. Each unique variant is closely related to the regulation of a specific cellular signaling. Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiological homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307970     DOI: 10.1161/01.RES.0000256354.95791.f1

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  259 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

4.  The biological activity of structurally defined inositol glycans.

Authors:  Meenakshi Goel; Viatcheslav N Azev; Marc d'Alarcao
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

Review 5.  Safety of sildenafil in infants*.

Authors:  Samira Samiee-Zafarghandy; P Brian Smith; Johannes N van den Anker
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

6.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

7.  A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

Authors:  Xian-Feng Huang; Wen-Tao Jiang; Li Liu; Fang-Chen Song; Xia Zhu; Gui-Lan Shi; Shu-Ming Ding; Heng-Ming Ke; Wei Wang; James M O'Donnell; Han-Ting Zhang; Hai-Bin Luo; Yi-Qian Wan; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

8.  The molecular and metabolic influence of long term agmatine consumption.

Authors:  Itzhak Nissim; Oksana Horyn; Yevgeny Daikhin; Pan Chen; Changhong Li; Suzanne L Wehrli; Ilana Nissim; Marc Yudkoff
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

9.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

Review 10.  Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Authors:  Sharon A Huang; Janette D Lie
Journal:  P T       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.